Viking Therapeutics (VKTX) is a publicly traded Healthcare sector company. As of May 20, 2026, VKTX trades at $29.41 with a market cap of $3.33B and a P/E ratio of -9.16. VKTX moved +3.56% today. Year to date, VKTX is -8.40%; over the trailing twelve months it is +2.69%. Its 52-week range spans $18.92 to $81.73. Analyst consensus is strong buy with an average price target of $95.63. Rallies surfaces VKTX's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
10 analysts cover VKTX: 0 strong buy, 10 buy, 0 hold, 0 sell, and 0 strong sell. The consensus rating is strong buy. The average price target is $95.63.
| Metric | Value |
|---|---|
| Price | $29.41 |
| Market Cap | $3.33B |
| P/E Ratio | -9.16 |
| EPS | $-3.19 |
| Dividend Yield | 0.00% |
| 52-Week High | $81.73 |
| 52-Week Low | $18.92 |
| Volume | 1.41M |
| Avg Volume | 0 |
| Revenue (TTM) | $0 |
| Net Income | $-359.64M |
| Gross Margin | 0.00% |
10 analysts cover VKTX: 0 strong buy, 10 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $95.63.